Brainstorm to present phase 2 progressive ms study results in oral presentation at 37th congress of ectrims

New york, oct. 1, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "phase 2 safety and efficacy study of intrathecal msc-ntf cells in progressive multiple sclerosis" will be presented in an oral presentation at the fully digital 37th congress of the european committee for treatment and research in multiple sclerosis (ectrims).  the presentation will be delivered by jeffrey cohen, m.d.
BCLI Ratings Summary
BCLI Quant Ranking